TY - JOUR
T1 - Patrolling monocytes scavenge endothelial-adherent sickle RBCs
T2 - A novel mechanism of inhibition of vaso-occlusion in SCD
AU - Liu, Yunfeng
AU - Zhong, Hui
AU - Bao, Weili
AU - Mendelson, Avital
AU - An, Xiuli
AU - Shi, Patricia
AU - Chou, Stella T.
AU - Manwani, Deepa
AU - Yazdanbakhsh, Karina
N1 - Funding Information:
The authors thank Kathy Tang (New York Blood Center) for mouse maintenance, Mihaela Barbu-Stevanovic (New York Blood Center) for cell sorting, and services provided by the Memorial Sloan Kettering Pathology Department for animal tissue sections and H&E staining. This study was supported by National Heart, Lung, and Blood Institute, National Institutes of Health grants R01HL121415 (K.Y.) and R01HL130139 (K.Y.).
Funding Information:
This study was supported by National Heart, Lung, and Blood Institute, National Institutes of Health grants R01HL121415 (K.Y.) and R01HL130139 (K.Y.).
Publisher Copyright:
© 2011 by The American Society of Hematology; all rights reserved.
PY - 2019/8/15
Y1 - 2019/8/15
N2 - Painful vaso-occlusive crisis (VOC) is the most common complication of sickle cell disease (SCD). Increasing evidence suggests that vaso-occlusion is initiated by increased adherence of sickle red blood cells (RBCs) to the vascular endothelium. Thus, the mechanisms that remove endothelial-attached sickle RBCs from the microvasculature are expected to be critical for optimal blood flow and prevention of VOC in SCD. We hypothesized that patrolling monocytes (PMos), which protect against vascular damage by scavenging cellular debris, could remove endothelial-adherent sickle RBCs and ameliorate VOC in SCD. We detected RBC (GPA1)-engulfed material in circulating PMos of patients with SCD, and their frequency was further increased during acute crisis. RBC uptake by PMos was specific to endothelial-attached sickle, but not control, RBCs and occurred mostly through ICAM-1, CD11a, and CD18. Heme oxygenase 1 induction, by counteracting the cytotoxic effects of engulfed RBC breakdown products, increased PMo viability. In addition, transfusions, by lowering sickle RBC uptake, improved PMo survival. Selective depletion of PMos in Townes sickle mice exacerbated vascular stasis and tissue damage, whereas treatment with muramyl dipeptide (NOD2 ligand), which increases PMo mass, reduced stasis and SCD associated organ damage. Altogether, these data demonstrate a novel mechanism for removal of endothelial attached sickle RBCs mediated by PMos that can protect against VOC pathogenesis, further supporting PMos as a promising therapeutic target in SCD VOC.
AB - Painful vaso-occlusive crisis (VOC) is the most common complication of sickle cell disease (SCD). Increasing evidence suggests that vaso-occlusion is initiated by increased adherence of sickle red blood cells (RBCs) to the vascular endothelium. Thus, the mechanisms that remove endothelial-attached sickle RBCs from the microvasculature are expected to be critical for optimal blood flow and prevention of VOC in SCD. We hypothesized that patrolling monocytes (PMos), which protect against vascular damage by scavenging cellular debris, could remove endothelial-adherent sickle RBCs and ameliorate VOC in SCD. We detected RBC (GPA1)-engulfed material in circulating PMos of patients with SCD, and their frequency was further increased during acute crisis. RBC uptake by PMos was specific to endothelial-attached sickle, but not control, RBCs and occurred mostly through ICAM-1, CD11a, and CD18. Heme oxygenase 1 induction, by counteracting the cytotoxic effects of engulfed RBC breakdown products, increased PMo viability. In addition, transfusions, by lowering sickle RBC uptake, improved PMo survival. Selective depletion of PMos in Townes sickle mice exacerbated vascular stasis and tissue damage, whereas treatment with muramyl dipeptide (NOD2 ligand), which increases PMo mass, reduced stasis and SCD associated organ damage. Altogether, these data demonstrate a novel mechanism for removal of endothelial attached sickle RBCs mediated by PMos that can protect against VOC pathogenesis, further supporting PMos as a promising therapeutic target in SCD VOC.
UR - http://www.scopus.com/inward/record.url?scp=85070778576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070778576&partnerID=8YFLogxK
U2 - 10.1182/blood.2019000172
DO - 10.1182/blood.2019000172
M3 - Article
C2 - 31076443
AN - SCOPUS:85070778576
SN - 0006-4971
VL - 134
SP - 579
EP - 590
JO - Blood
JF - Blood
IS - 7
ER -